Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA) + Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Allergies
Conditions
Allergies
Trial Timeline
Jun 1, 2005 → Jul 1, 2005
NCT ID
NCT00881634About Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA) + Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)
Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA) + Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA) is a phase 1 stage product being developed by Sandoz Group for Allergies. The current trial status is completed. This product is registered under clinical trial identifier NCT00881634. Target conditions include Allergies.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00881634 | Phase 1 | Completed |
Competing Products
5 competing products in Allergies
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MK0524 | Merck | Phase 2 | 52 |
| Dupilumab | Regeneron Pharmaceuticals | Phase 2 | 51 |
| Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg (Sandoz, USA) + Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA) | Sandoz Group | Phase 1 | 30 |
| Desloratadine + Zyrtec® (cetirizine) | Organon | Approved | 80 |
| Desloratadine + Zyrtec® (cetirizine) | Organon | Approved | 80 |